Julie Rubinstein, the President and Chief Operating Officer of Adaptive Biotechnologies Corporation, recently disclosed a series of stock transactions in an SEC filing. This filing, dated October 21, 2026, details both the acquisition and disposal of shares, which are significant for understanding the company's management activities and stock performance.
Background
Adaptive Biotechnologies Corporation, identified by CIK 0001478320, operates in the biological products sector, specifically focusing on products that do not involve diagnostic substances. The company is incorporated in Washington and has its fiscal year ending on December 31. It trades under the ticker symbol ADPT.
What the Filing Says
The filing reveals that Rubinstein executed multiple transactions involving Adaptive's common stock. On October 19, 2026, she acquired 11,881 shares at a price of $12.14 each. The following day, she sold 11,881 shares at a weighted average price ranging from $23.88 to $24.85. This pattern of acquisition and disposal continued with additional transactions on October 20 and 21, 2026, where she reported similar activities.
Impact
These transactions may affect investor sentiment towards Adaptive Biotechnologies, as they reflect the company's leadership's confidence in its stock performance. Rubinstein's actions, as a key executive, could signal to investors about the company's strategic direction and financial health.
What's Next
The filing does not say what happens next.